Allergenic Products Advisory Committee; Cancellation of Meeting, 17583 [2020-06513]
Download as PDF
<![CDATA[
17583
Federal Register / Vol. 85, No. 61 / Monday, March 30, 2020 / Notices
ANNUAL BURDEN ESTIMATES
Total/annual
number of
respondents
Instrument
Survey of NSCAW Adopted Youth, Young Adults, and Adults .......................
Survey of NSCAW Adoptive Parents ..............................................................
Estimated Total Annual Burden
Hours: 571
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Authority: Child Abuse Prevention and
Treatment and Adoption Reform Act of 1978.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–06491 Filed 3–27–20; 8:45 am]
BILLING CODE 4184–25–P
588
554
meeting was announced in the Federal
Register on February 24, 2020.
FOR FURTHER INFORMATION CONTACT:
Kathleen Hayes, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6307,
Silver Spring, MD 20993–0002, 301–
796–7864, kathleen.hayes@fda.hhs.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), and follow the prompts to the
desired center or product area. Please
call the Information Line for up-to-date
information on this meeting, which was
announced in the Federal Register of
February 24, 2020, 85 FR 10451.
Dated: March 24, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–06513 Filed 3–27–20; 8:45 am]
Allergenic Products Advisory
Committee; Cancellation of Meeting
AGENCY:
HHS.
ACTION:
Notice.
The meeting of the Allergenic
Products Advisory Committee
scheduled for May 15, 2020, is canceled.
The Allergenic Products Advisory
Committee meeting scheduled for May
15, 2020, to discuss and make
recommendations on the safety and
efficacy of Peanut (Arachis hypogaea)
Allergen Extract manufactured by DBV
Technologies, S.A, has been canceled to
allow time for the FDA to review
outstanding issues. The Agency intends
to continue evaluating the product and
will schedule an Advisory Committee
meeting in the future, as needed. The
lotter on DSKBCFDHB2PROD with NOTICES
VerDate Sep<11>2014
18:05 Mar 27, 2020
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by April 29,
2020.
SUMMARY:
SUMMARY:
Jkt 250001
294
277
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0680. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Tracking Network for PETNet,
LivestockNet, and SampleNet
The Center for Veterinary Medicine
and the Partnership for Food Protection
developed a web-based tracking
network (the tracking network) to allow
Federal, State, and Territorial regulatory
and public health Agencies to share
safety information about animal food.
Information is submitted to the tracking
network by regulatory and public health
Agency employees with membership
rights. The efficient exchange of safety
information is necessary because it
improves early identification and
evaluation of a risk associated with an
animal food product. We use the
information to assist regulatory
Agencies to quickly identify and
evaluate a risk and take whatever action
is necessary to mitigate or eliminate
exposure to the risk. Earlier
identification and communication with
respect to emerging safety information
may also mitigate the potential adverse
economic impact for the impacted
parties associated with such safety
issues. The tracking network was
developed under the requirements set
forth under section 1002(b) of the Food
and Drug Administration Amendments
Act of 2007 (FDAAA) (Pub. L. 110–085).
Section 1002(b) of the FDAAA required
FDA, in relevant part, to establish a pet
food early warning alert system.
AGENCY:
Food and Drug Administration,
.5
.5
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Tracking Network
for PETNet, LivestockNet, and
SampleNet
[Docket No. FDA–2020–N–0008]
Annual
burden hours
OMB Control Number 0910–0680—
Extension
[Docket No. FDA–2016–N–0736]
Food and Drug Administration
1
1
Average
burden hours
per response
BILLING CODE 4164–01–P
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Number of
responses per
respondent
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
ADDRESSES:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 85, Number 61 (Monday, March 30, 2020)]
[Notices]
[Page 17583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06513]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-0008]
Allergenic Products Advisory Committee; Cancellation of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Allergenic Products Advisory Committee
scheduled for May 15, 2020, is canceled. The Allergenic Products
Advisory Committee meeting scheduled for May 15, 2020, to discuss and
make recommendations on the safety and efficacy of Peanut (Arachis
hypogaea) Allergen Extract manufactured by DBV Technologies, S.A, has
been canceled to allow time for the FDA to review outstanding issues.
The Agency intends to continue evaluating the product and will schedule
an Advisory Committee meeting in the future, as needed. The meeting was
announced in the Federal Register on February 24, 2020.
FOR FURTHER INFORMATION CONTACT: Kathleen Hayes, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6307, Silver Spring, MD 20993-0002, 301-
796-7864, [email protected], or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), and follow the prompts to the desired center or product area.
Please call the Information Line for up-to-date information on this
meeting, which was announced in the Federal Register of February 24,
2020, 85 FR 10451.
Dated: March 24, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-06513 Filed 3-27-20; 8:45 am]
BILLING CODE 4164-01-P
